Medison Expands Leadership with Strategic Appointments
Strategic appointments reflect Medison's continued investment in global scale and operational excellence
Medison, the creator of a groundbreaking unified global commercialization platform, has made significant strides in enhancing its leadership team by appointing Shay Tamari as Chief Business Officer (CBO) and Tali Mirsky as Chief Legal & Compliance Officer (CLCO). These strategic appointments come as Medison ventures to strengthen its presence and operational effectiveness in the global biotechnology landscape.
Enhancing Global Capabilities for Future Growth
As Medison continues expanding its operational footprint and deepening collaborations with biotech firms worldwide, it recognizes the importance of robust leadership in realizing its vision. By bringing in executives with extensive experience and strategic insights, Medison aims to bolster its ability to innovate and effectively meet the diverse needs of markets across the globe. Both Shay and Tali possess the professional acumen necessary to drive the company forward amidst growing complexities.
Introducing Shay Tamari as Chief Business Officer
Shay Tamari, a distinguished addition to Medison’s executive team, will spearhead the company's corporate development strategy. With an impressive track record spanning over two decades in the pharmaceutical sector, including a significant tenure at Pfizer, Shay has a profound understanding of the U.S. biotech environment. His role focuses on identifying long-term growth opportunities and cultivating strategic partnerships that will enhance Medison's global operations.
Tali Mirsky Takes the Helm as Chief Legal & Compliance Officer
Tali Mirsky joins Medison with over 25 years of legal and compliance expertise in both private and public sectors, most recently with NICE. Her profound experience in managing global transactions, risk assessments, and corporate governance will fortify Medison's commitment to ethical practices and robust operational standards as it continues its expansion into diverse international markets.
Leadership Perspectives on New Appointments
Gil Gurfinkel, CEO of Medison, expressed enthusiasm about the new appointments, stating, "We are excited to welcome Shay and Tali to Medison's leadership team. Their experience in leading public companies and their deep industry expertise will be instrumental as we continue to scale our operations and bring breakthrough therapies to patients in underserved markets around the world. These appointments reflect our ongoing commitment to deliver on our ambitious mission."
Further highlighting the company’s vision, Meir Jakobsohn, Founder and Executive Chairman, remarked, "We have been building a unique global commercial platform, and we bring the best talent to support its expansion. Our leadership is dedicated to making breakthrough therapies accessible to patients around the globe, no matter their location."
The Impact of Medison's Unique Position in Biotech
Both Shay Tamari and Tali Mirsky are excited to join Medison during this critical phase of development. Shay stated, "I am thrilled to join Medison at such a pivotal time in its journey. The company’s unique platform and vision for global biotech commercialization are both compelling and needed. I look forward to fostering partnerships that will enhance access to groundbreaking therapies for patients."
Tali echoed this sentiment by emphasizing her commitment to excellence: "Medison is reshaping what global biotech commercialization can entail, and I am proud to be part of that. I look forward to supporting the company's growth by ensuring the highest standards of compliance and ethics are maintained throughout our operations."
Advancing Global Access to Innovative Therapies
The appointments of Shay and Tali highlight Medison’s ambitious goal of cultivating a leadership team that can drive its innovative platform. Their expertise will play a crucial role in helping biotech partners deliver their breakthroughs to more patients around the world, enhancing health outcomes in underserved regions.
About Medison
Medison is dedicated to redefining global biotech commercialization with a mission that aims to change lives. As a pioneering global commercialization platform, Medison collaborates with biotech companies to ensure the timely delivery of breakthrough therapies to patients globally, particularly those with rare and severe diseases.
Medison thrives on accelerating access and broadening reach in markets beyond the U.S., Western Europe, and Japan. Utilizing an affiliate-like model allows the company to deliver commercial, medical, and operational capabilities that enable biotech innovators to scale their efforts internationally without sacrificing localized impact.
Believing that every patient deserves equal opportunities for health and longevity, Medison champions the cause of ensuring equitable access to critical therapies, tirelessly working to manifest this belief across its operations.
Contact Information
Medison Pharma
Liat Lavi, VP Corporate Affairs
T: +972-52-6026450
